Table 1 Characteristics of 570 patients
From: Dental problems delaying the initiation of interferon therapy for HCV-infected patients
Men/Women | 274/296 | ||
Age (mean ± SD) years | 57.2 ± 11.6 | ||
Liver disease | AH-C | 1 | (0.2%) |
CH-C | 471 | (82.6%) | |
CH-(B+C) | 3 | (0.5%) | |
CH-C and post HCC treatment | 20 | (3.5%) | |
LC-C | 45 | (7.9%) | |
LC-C and post HCC treatment | 30 | (5.3%) | |
Peg-IFN therapy | Peg-IFN alfa-2a monotherapy | 104 | (18.2%) |
Peg-IFN alfa-2a monotherapy and trial | 1 | (0.2%) | |
Peg-IFN alfa-2a/RBA | 14 | (2.5%) | |
Peg-IFN alfa-2a/RBA and trial | 5 | (0.9%) | |
Peg-IFN alfa-2b/RBA | 438 | (76.8%) | |
Peg-IFN alfa-2b/RBA→Peg-IFN alfa-2a monotherapy | 4 | (0.7%) | |
Peg-IFN alfa-2b/RBA→Peg-IFN alfa-2a monotherapy→Peg-IFN alfa-2a/RBA | 1 | (0.2%) | |
Peg-IFN alfa-2b/RBA→Peg-IFN alfa-2a monotherapy→Peg-IFN alfa-2b/RBA | 1 | (0.2%) | |
Peg-IFN alfa-2b/RBA→Peg-IFN alfa-2a/RBA | 2 | (0.4%) | |
HCV genotype | 1a | 2 | (0.4%) |
1a or 1b | 1 | (0.2%) | |
1b | 401 | (70.4%) | |
2a | 121 | (21.2%) | |
2b | 24 | (4.2%) | |
3a | 1 | (0.2%) | |
combination (1a and 1b) | 1 | (0.2%) | |
combination (1b and 2b) | 1 | (0.2%) | |
combination (1b and 3a) | 1 | (0.2%) | |
combination (2a and 2b) | 2 | (0.4%) | |
indeterminable | 3 | (0.5%) | |
untested | 12 | (2.1%) | |